Evidence map›Paper›PMID 17143611›Full record

ArticleCancer immunology, immunotherapy : CII2007

Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.

Farah Aladin, Georg Lautscham, Elizabeth Humphries, Judy Coulson, Neil Blake

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. IFN-γ treatment protocol for MHC-IJournal for immunotherapy of cancer · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. The use of signal peptide domains as vaccine candidates.Human vaccines & immunotherapeutics · 2014
    Review
  8. Article
  9. Article
  10. Review
  11. Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Farah AladinDivision of Medical Microbiology, University of Liverpool, Daulby Street, Liverpool, UK.
Georg Lautscham
Elizabeth Humphries
Judy Coulson
Neil Blake
University of Liverpool · GBUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is becoming increasingly apparent that the majority of tumours display defects in the MHC class I antigen processing pathway, particularly low levels of the transporters-associated with antigen processing (TAP) and tapasin. Thus, immunotherapy approaches targeting such tumours with CD8+ cytotoxic T lymphocytes (CTL) requires strategies to overcome these defects. Previously we had identified an antigen processing pathway by which cytosolically derived hydrophobic peptides could be presented in the absence of TAP. Here we show in the tapasin-negative cell line 721.220 that a number of these hydrophobic TAP-independent peptides can also be presented in a tapasin-independent manner. Yet when these experiments were extended to tumour cell lines derived from small cell lung cancer (SCLC), which we show to be tapasin deficient in addition to TAP-negative, the TAP-, tapasin-independent peptides were not presented. This lack of presentation could be rectified by pre-treatment of SCLC cells with IFNgamma. Alternatively, by directing the TAP-, tapasin-independent peptides into the endoplasmic reticulum (ER) via an ER signal sequence, these peptides were presented efficiently by SCLC cells. We infer from this data that the TAP-independent pathway for presentation of hydrophobic peptides generates a low concentration of peptide in the ER and, for tumour cells which also lack tapasin, this concentration of antigenic peptide is insufficient to load onto MHC class I molecules. Thus, for immunotherapeutic approaches to target SCLC and other tumours with defects in the MHC class I antigen processing pathway it will be important to consider strategies that address tapasin-defects.

Indexed as

Antigen PresentationAntigens, ViralATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2ATP Binding Cassette Transporter, Subfamily B, Member 3Carcinoma, Small CellCD8-Positive T-LymphocytesCell Line, TransformedCell Line, TumorCytosolEndoplasmic ReticulumHerpesvirus 4, HumanHistocompatibility Antigens Class IHLA-A24 AntigenHLA-A2 AntigenHLA-A AntigensAntigens, ViralATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2ATP Binding Cassette Transporter, Subfamily B, Member 3BRLF1 protein, Human herpesvirus 4EBV-associated membrane antigen, Epstein-Barr virusEpstein-Barr virus early antigen diffuse componentHistocompatibility Antigens Class IHLA-A24 AntigenHLA-A2 AntigenHLA-A AntigensImmediate-Early ProteinsMembrane Transport ProteinsPeptide FragmentsPhosphoproteinsProtein Sorting SignalsSM protein, Human herpesvirus 4TAP1 protein, humanTAP2 protein, humantapasinTrans-ActivatorsViral Matrix ProteinsViral Proteins

Identifiers

PMID17143611
PMCPMC11031051
OpenAlexW1982847674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.